Our Technology
Unleash the therapeutic potential of active pharmaceutical ingredients previously limited by unfavorable toxicities, in vivo stabilities, and pharmacokinetic profiles; enhance treatment efficacies and transform the target molecule with pharmacologically distinct mechanisms of action with Tripartite Therapeutics' proprietary OmniLink® and Polarpeutic® technologies.
Technology
OmniLink®
Tripartite Therapeutics' OmniLink® technology can achieve stable conjugation of cytotoxic drugs, immune adjuvants and other small bio- and chemical molecules to antibodies or antibody fragments with minimal premature release of the payloads in systemic circulation, enabling drugs with exceptionally high potency that would otherwise be hampered by dose-limiting toxicities as payloads. A high ratio of conjugated molecule per antibody (i.e. drug-antibody ratio, DAR) further augments ADC's efficacy toward all classes of tumor with different expression levels of tumor antigen. The versatility of the OmniLink® technology even allows for treatment modalities with dual mechanisms of action via dual-payload conjugations. We expect the endless treatment possibilities offered by the combination of treatment modalities to culminate both first-in-class and best-in-class treatment options in our continuous flow of product pipelines.
Polarpeutic®
An ideal antibody drug conjugate (ADC) should exert highly potent tumor eradication activity while causing minimal collateral damage to healthy cells. In practice, the effectiveness of current ADCs is hindered by dose-limiting toxicities associated with the drug payload. With Polarpeutic® technology, ADC payloads, which are primarily hydrophobic in nature, can be rendered hydrophilic while retaining its pharmacological effects. Further, Polarpeutic® drug payloads make ADCs with higher drug-to-antibody ratios (DAR) without rendering the overall ADCs hydrophobic a reality, thereby minimizing the risk of aggregation, rapid RES clearance and immune toxicity. When released from the ADC, Polarpeutic® payloads are poor substrates for cancer multi-drug resistance (MDR) transporters as well as less capable of diffusion across the lipid-bilayer of the cellular membrane, making Polarpeutic® drug payloads less toxic and more efficacious than current leaders in approved ADC drugs as demonstrated in animal models. The technology has been successfully applied to a wide range of cytotoxic molecules including maytansinoids, camptothecin analogues, as well as non-cytotoxic payloads such as toll-like receptor agonists (TLR 7/8) for immuno-oncology.
Applications
Cytotoxic Payload Conjugates
Despite the promise of being the “magic bullet” treatment, ADCs have so far failed to deliver meaningful improvement over existing treatment options combining protein drugs and small molecule drugs. Challenges faced by current ADCs include: (1) Hydrophobic ADC molecule is rapidly eliminated by RES, resulting in not only immune toxicity but little drug arriving at the site of action; (2) Released free payload causes systemic and hepatic toxicities; (3) In fear of aggregation and toxicity, ADC designs restricted to low DAR underlie the poor clinical performance for cancer types with low target antigen expression. All such challenges are solved with our Polarpeutic® and OmniLink® technologies.
Immune Stimulating Payload Conjugates
Cancer immune therapy seeks to harness the body's natural immune system in the fight against cancer without the side-effects of cytotoxic payloads. Modulating the immune system can be dangerous, running the risk of self-escalating cytokine storms with lethal consequences. Tripartite's OmniLink® and Polarpeutic® technologies are the ideal solution to realize the potential of immune-modulating payloads. Our OmniLink® linker ensures payload stability during circulation while Polarpeutic® payload prevents itself from crossing the cellular membrane, ensuring that the immune-response is mainly limited to the tumor environment targeted by the antibody.
Dual-payload Conjugates
Carrying two different payloads with complementary mechanisms of action is an effective means for countering drug resistance and improving therapeutic outcomes through synergistic effect exerted by the different payloads. Using Tripartite's OmniLink® technology, the same linker can be broadly adapted to the different payloads while rendering simultaneous release of them. In combination with our Polarpeutic® technology, a high drug-to-antibody ratio (DAR) of 4+4 can be achieved for dual payload ADCs.